billHR8119Event Thursday, March 26, 2026Analyzed

HOPE with Fertility Services Act

Neutral
Impact2/10

Summary

HR8119, the HOPE with Fertility Services Act, has been introduced in the House and referred to the Committee on Education and Workforce. This bill mandates group health plans and issuers to cover infertility and iatrogenic infertility treatments, including fertility preservation services under specific medical conditions. As an early-stage bill, its direct market impact is currently limited.

Key Takeaways

  • 1.HR8119 mandates group health plans to cover infertility and iatrogenic infertility treatments.
  • 2.The bill does not involve direct federal funding but shifts costs to private health insurers.
  • 3.Potential beneficiaries include fertility service providers and related medical technology companies.
  • 4.The bill is in an early legislative stage, having only been introduced and referred to committee.

Market Implications

The HOPE with Fertility Services Act, if enacted, would structurally expand the market for fertility treatments and related services by mandating coverage from group health plans. This would primarily benefit companies operating in the fertility clinic sector, as well as pharmaceutical companies and medical device manufacturers specializing in reproductive health. Conversely, health insurance companies offering group coverage would likely experience increased claims costs, which could influence their pricing strategies and benefit designs. As the bill is in its initial committee review phase, there are no immediate market-wide implications or specific stock movements to report.

Full Analysis

On March 26, 2026, HR8119, titled the "Helping to Optimize Patients' Experience with Fertility Services Act" or the "HOPE with Fertility Services Act," was introduced in the House of Representatives by Rep. Nunn of Iowa and referred to the House Committee on Education and Workforce. The bill's primary objective is to amend the Employee Retirement Income Security Act of 1974 to ensure that group health plans and health insurance issuers offering group health insurance coverage provide benefits for the treatment of infertility and iatrogenic infertility, including standard fertility preservation services when medically necessary treatments cause or are expected to cause iatrogenic infertility. This legislation does not authorize or appropriate specific federal funding. Instead, it mandates coverage requirements for private group health plans and health insurance issuers. The financial burden, if the bill were to pass, would fall on these entities through increased claims for infertility treatments and associated services. This could lead to adjustments in premium structures or benefit offerings within the private insurance market. Companies providing fertility services and related medical technologies would see an expansion in their addressable market, as more individuals would have insurance coverage for these treatments. Structural beneficiaries, should this bill advance, would include companies involved in fertility clinics, reproductive endocrinology services, and manufacturers of fertility-related pharmaceuticals and medical devices. Conversely, health insurance providers offering group plans would face increased costs associated with covering these mandated services. Given the bill's early stage, there are no immediate market-wide shifts or specific company impacts to report. The bill has 12 cosponsors, indicating some bipartisan support, but its referral to committee means it has a long legislative path ahead. To progress, HR8119 would need to be considered and voted on by the House Committee on Education and Workforce, then potentially passed by the full House, followed by similar processes in the Senate, and finally signed into law by the President. As of today, April 13, 2026, the bill remains in the initial committee review phase.

Market Impact Score

2/10
Minimal ImpactModerateMajor Market Event